Affordable Access

deepdyve-link
Publisher Website

Skp2: a novel potential therapeutic target for prostate cancer.

Authors
  • Wang, Zhiwei1
  • Gao, Daming
  • Fukushima, Hidefumi
  • Inuzuka, Hiroyuki
  • Liu, Pengda
  • Wan, Lixin
  • Sarkar, Fazlul H
  • Wei, Wenyi
  • 1 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. , (Israel)
Type
Published Article
Journal
Biochimica et Biophysica Acta
Publisher
Elsevier
Publication Date
January 2012
Volume
1825
Issue
1
Pages
11–17
Identifiers
DOI: 10.1016/j.bbcan.2011.09.002
PMID: 21963805
Source
Medline
License
Unknown

Abstract

Prostate cancer is the most frequently diagnosed tumor in men and the second most common cause of cancer-related death for males in the United States. It has been shown that multiple signaling pathways are involved in the pathogenesis of prostate cancer, such as androgen receptor (AR), Akt, Wnt, Hedgehog (Hh) and Notch. Recently, burgeoning amounts of evidence have implicated that the F-box protein Skp2 (S-phase kinase associated protein 2), a well-characterized oncoprotein, also plays a critical role in the development and progression of prostate cancer. Therefore, this review discusses the recent literature regarding the function and regulation of Skp2 in the pathogenesis of prostate cancer. Furthermore, we highlight that Skp2 may represent an attractive therapeutic target, thus warrants further development of agents to target Skp2, which could have significant therapeutic impact on prostate cancer.

Report this publication

Statistics

Seen <100 times